drugset / Trial / NCT02765633

Cangrelor Neonatal PK/PD and Safety Study

NCT02765633

Phase 1 Completed 22 enrolled Chiesi Farmaceutici S.p.A.
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to assess the PK/PD and safety profile of cangrelor in neonatal participants at risk of thrombosis.

Timeline

Start
2017-01-03
Primary completion
2019-08-31
Completion
2019-12-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Cangrelor Small molecule 0.25 ug/kg Other
Subject Cangrelor Small molecule 0.5 ug/kg Other